1[18]Kollias G,Kontoyiannis D.Role of TNF/TNFR in antoimmunity:specific TNF receptor blockade may be advantageous to anti-TNF treatments.Cytokine Growth Factor Rev,2002,13:315-321.
2[19]Hommes DW,van de Heisteeg BH,van der Spek M,et al.Infliximab treatment for Crohn's disease:one-year experience in a Dutch academic hospital.Inflamm Bowel Dis,2002,8:81-86.
3[20]Collins SM,Piche T,Rampal P.The putative role of inflammation in the irritable bowel syndrome.Gut,2001,49:743-745.
4[21]Podolsky DK.The current future understanding of inflammatory bowel disease.Best Pract Res Clin Gastroenterol,2002,16:933-943.
5[22]Matthews SG.Early programming of the hypothalamo-Pituitary-a-drenal axis.Trends Endocrinol Metab,2002,13:373-380.
6[23]Cario E,Podolsky DK.Differentialal alteration in intestinal epithelial cell expression of toll-like receptor 3(TLR3)and TLR4 in inflammatory bowel disease.Infect Immun,2000,68:7010-7017.
7[24]Balsari A,Ceccarelli A,Dubini F,et al.The fecal microbial population in the irritable bowel syndrome.Microbiologica,1982,5:185-194.
8[25]Pimentel M Chow EJ.Lin HC.Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome.a double-blind,randomized,placebo-controlled study.Am J Gustroenterol,2003,98:412-419.
9[1]Spiller RC.Neuropathology of IBS?Gastroenterology,2002,123:2144-2147.
10[2]Gwee KA,Collins SM,Marshall JS,et al.Evidence of inflammatory pathogenesis in post-infectious irritable bowel syndrome.Gastroen-terology,1998,114:A758.
